Gonzales Anita sold $9K of RVTY

Gonzales Anita (Vice President and CAO) sold 85 shares of REVVITY, INC. (RVTY) at $109.48 on 2026-07-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gonzales Anita
Published Jul 22, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RVTY
Neutral
high confidence
Mentioned
$RVTY
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVTYNeutralLow
01

Why it matters

The disclosure provides transparency on an officer’s planned selling activity but does not introduce new company fundamentals or catalysts.

02

Market read

Primarily informational for insider-trading trackers; limited expected impact on trading decisions.

03

What to watch

The sale size is small ($9.3K) and does not include any buy/sell pattern context beyond this single transaction.

Relevance 2/10Novelty 2/10Timing: Filed on 2026-07-22 after-hours, reflecting a 2026-07-20 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Revvity, Inc.

Company-level read

Ticker impact

$RVTYNeutralHigh confidence
Context

Revvity CAO Anita Gonzales sold 85 shares on 2026-07-20 at $109.48/share under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a small, pre-planned open-market sale by an officer, with no accompanying guidance, operational change, or enforcement action disclosed.

Market effects

No sector read-across; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with private concerns; traders may still monitor for follow-on sales.

Key entities

  • RVTY

    Revvity, Inc., the issuer of the Form 4 insider transaction.

  • Anita Gonzales

    Vice President and CAO who sold 85 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RVTYHighAI 8/10

Revvity Q3 Earnings Call Highlights

Revvity reported Q3 earnings, highlighting AI-driven demand growth in high-content screening instruments, with revenue up 4% and backlog expansion across categories. Diagnostics revenue reached $330M, with mid-single-digit growth. The company raised its 2026 organic growth outlook to 5% and expects Q4 revenue of ~$755M. Margins improved, and free cash flow was strong. Revvity plans to discuss its AI strategy and outlook at an Investor Day event.

$RVTYMedAI 8/10

Revvity Inc (RVTY) (Q3 2026) Earnings Call Highlights: Strong Organic Growth

Revvity Inc (RVTY) reported Q3 2026 earnings, highlighting 7% organic growth but guiding Q4 growth down to 5% due to lower reagent and software growth. APAC saw a low single-digit decline, and China's immunodiagnostics business remains a margin headwind. Software growth is expected to moderate, and AI demand is emerging but not yet quantified. The company confirmed sustainable incremental margins in the low 40s and expects a durable pharma biotech recovery.

$RVTYHigh

Revvity (RVTY) Q3 2026 Earnings Call Transcript

Revvity (RVTY) reported Q3 2026 earnings, highlighting AI-driven demand growth across its portfolio, including high-content screening, life sciences reagents, and detection instruments. The company expects 5% full-year organic growth and adjusted EPS of $5.40-$5.45, up from initial forecasts. Revvity also launched new AI-native offerings in its signals software business and a new diagnostic kit for early type 1 diabetes detection in Europe.

$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.